Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04139798 · ClinicalTrials.gov registry record · Phase 3
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 599
- Enrollment target
NCT04139798 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 599 participants.
The verdict
NCT04139798, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 599 participants
- Enrollment target
Study Summary
This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
Interventions
- DRUG Placebo
- DRUG NOV03
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2021-03-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04139798
The ClinicalTrials.gov registry entry for NCT04139798 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 599 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04139798 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04139798 about?
NCT04139798 is a clinical study titled "Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)". This trial will evaluate the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
What is the current status of trial NCT04139798?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 599 participants. The study started on 2020-07-20. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT04139798?
The interventions under investigation include: Placebo (DRUG), NOV03 (DRUG).
Who is sponsoring clinical trial NCT04139798?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.